-
Clinical Pharmacology and Therapeutics 1967
Topics: Adult; Blood Pressure Determination; Body Weight; Female; Hematocrit; Humans; Hypertension; Liver Function Tests; Male; Methyldopa; Middle Aged; Prolactin; Pulse
PubMed: 6021583
DOI: 10.1002/cpt196782224 -
British Medical Journal Aug 1976
Topics: Humans; Hypertension; Methyldopa; Relaxation Therapy; Yoga
PubMed: 782653
DOI: 10.1136/bmj.2.6034.525 -
Anaesthesia and Intensive Care May 1974
Topics: Aged; Autoantibodies; Autoimmune Diseases; Coombs Test; Humans; Hypertension; Male; Methyldopa
PubMed: 4447239
DOI: 10.1177/0310057X7400200211 -
Gastroenterology Jan 1976
Topics: Adult; Cholestasis; Humans; Male; Methyldopa
PubMed: 1245279
DOI: No ID Found -
Ugeskrift For Laeger Mar 1973
Topics: Humans; Methyldopa; Parkinson Disease, Secondary
PubMed: 4719917
DOI: No ID Found -
Tidsskrift For Den Norske Laegeforening... Nov 1977
Topics: Chemical and Drug Induced Liver Injury; Humans; Liver; Methyldopa
PubMed: 594960
DOI: No ID Found -
Hypertension in Pregnancy 2012Investigation of methyldopa and nifedipine effects on maternal and fetal hemodynamics in women with mild gestational hypertension during the third pregnancy trimester.
OBJECTIVE
Investigation of methyldopa and nifedipine effects on maternal and fetal hemodynamics in women with mild gestational hypertension during the third pregnancy trimester.
METHODS
A prospective cohort study. Methyldopa effects were followed in 28 patients, and nifedipine effects in another 28 patients. There were also 28 healthy controls.
RESULTS
Uterine artery blood velocity waveform indices were improved only by nifedipine. Neither of the drugs affected the indices in umbilical and fetal middle cerebral artery. Both drugs normalized maternal blood pressure and pulse.
CONCLUSIONS
Methyldopa and nifedipine did not show clinically significant influence on umbilical artery and fetal cerebral blood flow.
Topics: Adult; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertension, Pregnancy-Induced; Methyldopa; Nifedipine; Placental Circulation; Pregnancy; Prospective Studies
PubMed: 21219124
DOI: 10.3109/10641955.2010.525274 -
British Journal of Clinical Pharmacology 19801. The antihypertensive effects of the new phenylacetylguanidine compound, guanfacine, a sympathetic inhibitor with a central site of action, were compared with... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
1. The antihypertensive effects of the new phenylacetylguanidine compound, guanfacine, a sympathetic inhibitor with a central site of action, were compared with methyldopa in 20 out-patients with essential or renal hypertension (WHO grade I-II). 2. During a 6-week period in randomized cross-over conditions, guanfacine 3.5 mg daily caused a mean decrease of 24% in mean arterial blood pressure (MAP). A normalization of blood pressure (BP < 145/95 mm Hg) was achieved in 50% of the patients and a 'good control' (BP < 160/100 mm Hg; > 145/95 mm Hg) in 90%. 3. Methyldopa 1.2 g daily led to a mean decrease in MAP of 12%. Normalization of blood pressure occurred in 15% and a 'good control' was achieved with 45% of the patients. Failure due to intolerance or ineffectiveness was observed in 40% of patients. 4. During therapy with guanfacine the following side-effects were noted: dryness of the mouth (n = 5), marked sedation (n = 2), constipation (n = 2), orthostasis (n = 1), collapse (n = 1) and atrioventricular block grade I on ECG (n = 1). Methyldopa caused headaches (n = 4), gastrointestinal disturbances (n = 4) and dryness of the mouth (n = 1). 5. The experience so far available seems to indicate that guanfacine is an effective antihypertensive drug which is more active than methyldopa in the doses used in this study.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Female; Guanfacine; Guanidines; Humans; Hypertension; Male; Methyldopa; Middle Aged; Phenylacetates
PubMed: 6994779
DOI: 10.1111/j.1365-2125.1980.tb04905.x -
Advances in Drug Research 1967
Review
Topics: Animals; Autonomic Nervous System; Cats; Central Nervous System; Chemical Phenomena; Chemistry; Dogs; Drug Synergism; Guinea Pigs; Humans; Hypertension; Methyldopa; Methyltyrosines; Mice; Norepinephrine; Rats; Stereoisomerism
PubMed: 4902343
DOI: No ID Found -
Drug Metabolism and Disposition: the... 1984In a crossover study, the pivaloyloxyethyl ester (POE) of methyldopa, labeled either with 3H in the methyldopa moiety or 14C in the pivalic acid moiety, was administered...
In a crossover study, the pivaloyloxyethyl ester (POE) of methyldopa, labeled either with 3H in the methyldopa moiety or 14C in the pivalic acid moiety, was administered orally to four volunteers in 1000-mg single doses (equivalent to 500 mg of methyldopa). The majority (93%) of either the 3H- or 14C-labeled dose was excreted in the urine. Methyldopa, which was assayed by a fluorometric technique, peaked (approximately 6 micrograms/ml) at 1 hr in the plasma. Forty-five per cent of the dose was excreted as methyldopa as opposed to 18% normally seen after oral methyldopa dosages. Intact POE was absent in the urine of three volunteers and present in only trace amounts in urine from a fourth volunteer. Thus, the oral dose of POE was well absorbed and rapidly hydrolyzed to methyldopa. After oral administration of methyldopa, methyldopa sulfate is the principal urinary metabolite in man. However, after administration of POE, a relatively small fraction (13%) of the dose was excreted as methyldopa sulfate. The major urinary metabolite of POE, other than methyldopa, was 3-OCH3 methyldopa. Methyldopamine was a minor metabolite. It was concluded that a shift from sulfation to methylation occurred in the metabolic profile of methyldopa when it was administered as POE and that the metabolites of POE (including conjugated pivalic acid) were rapidly eliminated from the body.
Topics: Administration, Oral; Adolescent; Adult; Biotransformation; Chromatography, Thin Layer; Gas Chromatography-Mass Spectrometry; Humans; Male; Methyldopa; Middle Aged
PubMed: 6144491
DOI: No ID Found